The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).

For more information: https://clinicaltrials.gov/study/NCT06292013 

Would you like to receive more information about participating in this clinical study? Fill out your contact details below and our research team will be in touch within 24 hours.